Efficacy of S-1 monotherapy for non-small cell lung cancer after the failure of two or more prior chemotherapy regimens

  • Authors:
    • Osamu Takakuwa
    • Tetsuya Oguri
    • Ken Maeno
    • Hiroaki Ozasa
    • Yasuhito Iwashima
    • Mikinori Miyazaki
    • Hideharu Kunii
    • Yuko Takano
    • Toshiyuki Mori
    • Shigeki Sato
    • Ryuzo Ueda
  • View Affiliations

  • Published online on: January 1, 2010     https://doi.org/10.3892/ol_00000027
  • Pages: 147-150
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The efficacy and safety of S-1 monotherapy for patients with advanced or recurrent non-small cell lung cancer (NSCLC) after the failure of two or more prior chemotherapy regimens were investigated. Records of 36 patients with advanced or recurrent NSCLC who received S-1 monotherapy between January 2005 and December 2008, following the failure of previous chemotherapy, were reviewed retrospectively at two institutions. S-1 was given orally twice daily on days 1-28 every six weeks; the dose was based on body surface area. The median number of prior chemotherapy regimens was three (range 2-5), and that of courses given per patient was two (range 1-10). No patient achieved complete response, 4 patients (11.1%) achieved partial response, 10 patients (27%) had stable disease and 18 patients (50%) had progressive disease. The median progression-free survival was 3 months and the median overall survival was 15.2 months. No grade 4 hematological toxicity was noted. Grade ≥3 non-hematological toxicities were observed in 5 patients (13.9%). No deaths related to S-1 monotherapy occurred. S-1 monotherapy exhibits activity with acceptable toxicity as third-line or subsequent chemotherapy for advanced NSCLC.
View Figures
View References

Related Articles

Journal Cover

January-February 2010
Volume 1 Issue 1

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Takakuwa O, Oguri T, Maeno K, Ozasa H, Iwashima Y, Miyazaki M, Kunii H, Takano Y, Mori T, Sato S, Sato S, et al: Efficacy of S-1 monotherapy for non-small cell lung cancer after the failure of two or more prior chemotherapy regimens . Oncol Lett 1: 147-150, 2010
APA
Takakuwa, O., Oguri, T., Maeno, K., Ozasa, H., Iwashima, Y., Miyazaki, M. ... Ueda, R. (2010). Efficacy of S-1 monotherapy for non-small cell lung cancer after the failure of two or more prior chemotherapy regimens . Oncology Letters, 1, 147-150. https://doi.org/10.3892/ol_00000027
MLA
Takakuwa, O., Oguri, T., Maeno, K., Ozasa, H., Iwashima, Y., Miyazaki, M., Kunii, H., Takano, Y., Mori, T., Sato, S., Ueda, R."Efficacy of S-1 monotherapy for non-small cell lung cancer after the failure of two or more prior chemotherapy regimens ". Oncology Letters 1.1 (2010): 147-150.
Chicago
Takakuwa, O., Oguri, T., Maeno, K., Ozasa, H., Iwashima, Y., Miyazaki, M., Kunii, H., Takano, Y., Mori, T., Sato, S., Ueda, R."Efficacy of S-1 monotherapy for non-small cell lung cancer after the failure of two or more prior chemotherapy regimens ". Oncology Letters 1, no. 1 (2010): 147-150. https://doi.org/10.3892/ol_00000027